AFP and cancer: However, the survival after correction for lead-time in the AFP group, together with adjustment for variables related to initial BCLC stage of tumor and its treatment, revealed comparable benefits in the AFP and AFP+US groups regarding both overall and cancer deaths (adjusted HR [95% CI], 0.87 [0.67–1.12], P = 0.276 and 0.81 [0.60–1.10], P = 0.178, respectively).